BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of BridgeBio Oncology Therapeutics (NASDAQ:BBOT – Free Report) from a sell rating to a hold rating in a research note released on Saturday morning,Wall Street Zen reports.

Several other research analysts have also commented on the stock. JPMorgan Chase & Co. decreased their price target on shares of BridgeBio Oncology Therapeutics from $25.00 to $23.00 and set an “overweight” rating for the company in a report on Friday, September 11th. Wedbush lowered their price objective on shares of BridgeBio Oncology Therapeutics to $9.00 and set an “outperform” rating for the company in a research report on Wednesday, November 11th. Stifel Nicolaus dropped their price objective on shares of BridgeBio Oncology Therapeutics from $23.00 to $15.00 and set a “buy” rating on the stock in a research note on Wednesday, September 9th. Canaccord Genuity Group cut their target price on shares of BridgeBio Oncology Therapeutics from $23.00 to $20.00 and set a “buy” rating on the stock in a report on Wednesday, September 9th. Finally, Leerink Partners decreased their target price on BridgeBio Oncology Therapeutics to $27.00 and set an “outperform” rating for the company in a research note on Thursday, September 10th. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $19.33.

View Our Latest Analysis on BBOT

BridgeBio Oncology Therapeutics Stock Performance

Shares of BBOT opened at $1.98 on Friday. The business’s fifty day moving average price is $3.51 and its 200 day moving average price is $7.63. BridgeBio Oncology Therapeutics has a 12-month low of $1.97 and a 12-month high of $14.87.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT – Get Free Report) last released its earnings results on Tuesday, November 10th. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.22. As a group, research analysts anticipate that BridgeBio Oncology Therapeutics will post -2.75 EPS for the current year.

Hedge Funds Weigh In On BridgeBio Oncology Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in BBOT. Opaleye Management Inc. increased its position in BridgeBio Oncology Therapeutics by 1,213.8% in the 2nd quarter. Opaleye Management Inc. now owns 700,000 shares of the company’s stock valued at $5,334,000 after acquiring an additional 646,718 shares during the period. Regents of The University of California bought a new stake in BridgeBio Oncology Therapeutics during the 3rd quarter valued at $10,289,000. Granahan Investment Management LLC acquired a new position in BridgeBio Oncology Therapeutics during the 1st quarter worth $2,068,000. Goldman Sachs Group Inc. boosted its position in BridgeBio Oncology Therapeutics by 134.7% during the 3rd quarter. Goldman Sachs Group Inc. now owns 239,614 shares of the company’s stock worth $982,000 after acquiring an additional 137,529 shares during the period. Finally, Marshall Wace LLP acquired a new position in BridgeBio Oncology Therapeutics during the 3rd quarter worth $1,980,000. 54.89% of the stock is currently owned by institutional investors and hedge funds.

About BridgeBio Oncology Therapeutics

(Get Free Report)

BridgeBio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted treatments for cancers driven by RAS and related signaling pathways. The company’s research centers on disrupting molecular signals that help cancer cells grow and survive. Its development programs include drug candidates designed to target KRAS mutations and interactions between RAS and other cancer-related proteins. These investigational medicines are being studied for potential use in solid tumors; they are not approved treatments.

Further Reading

Analyst Recommendations for BridgeBio Oncology Therapeutics (NASDAQ:BBOT)

Receive News & Ratings for BridgeBio Oncology Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Oncology Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.